News - OxyDial Inc

May 27 2024

Cells collected from 1st SCD patient receiving bluebird bio’s new SCD gene therapy, Lyfgenia

Following their recent FDA approval and more than a decade of development, biotech firm Bluebird Bio has announced the completion of its first cell collection for their Sickle Cell Disease …

OxyDial

May 10 2024

National Health Service approves Pfizer SCD treatment, Voxelotor

In an exciting announcement from the United Kingdom’s National Health Service (NHS), patients with Sickle Cell Disease can now be prescribed Voxelotor, a Pfizer-developed drug that can significantly improve quality …

OxyDial

May 7 2024

Etavopivat is Efficient for Sickle Cell Disease Treatment, as Shown in Phase I Study

Preliminary Phase I results for etavopivat show promising impact on sickle cell disease (SCD) in trial patients. Led by Dr. Saraf Santosh of the University of Illinois Chicago, the ongoing …

OxyDial

Apr 23 2024

Roxadustat Test Results Demonstrate Safe Treatment for Anemia in Myelofibrosis

The latest results from the ongoing tests of AstraZeneca Roxadustat show that the oral drug may be a safe and effective option for patients with myelofibrosis who develop anemia due …

OxyDial

Apr 12 2024

FDA Grants Bristol Myers Reblozyl Approval For a Broader Patients Anemia Treatment

The FDA has approved the widespread use of @Bristol Myers Squibb’s drug Reblozyl for treating anemia in adult patients with beta-thalassemia who require regular blood transfusions and suffer from low-to-intermediate-risk …

OxyDial

Apr 4 2024

Pfizer’s Oxbryta Prevents Sickling in Red Blood Cells for Pediatric SCD Patients

Ongoing stage 2a clinical trials for Pfizer‘s Oxbryta (voxelotor) continue to show successful results in pediatric patients. Approved for treating SCD, the oral medication prevents red blood cells from sickle-shaping …

OxyDial

Mar 28 2024

Pfizer Receives Approval for Osivelotor Phase 2/3 Trials in India

A Phase 2/3 multicenter study of Osivelotor has been approved to proceed by India’s Central Drugs Standard Control Organisation (CDSCO). Aimed at treating Sickle Cell Disease, the drug (GBT021601) has …

OxyDial

Mar 21 2024

Phase 3 ENERGIZE Study Shows the Potential of Mitapivat for Thalassemia Patients

A clinical trial led by Dr. Ali Taher at the American University of Beirut Medical Center, shows that Mitapivat has potential benefits for non-transfusion dependent thalassemia patients. Developed by Agios …

OxyDial

Mar 14 2024

New Low-Cost Diagnostics for Sickle Cell Disease

Tim Randolph has been recognized by the National Academy of Inventors for his innovative work in developing more accessible diagnostics for sickle cell disease. The research has led to the …